Literature DB >> 4027149

The metabolism and pharmacokinetics of nicardipine hydrochloride in man.

D J Graham, R J Dow, D J Hall, O F Alexander, E J Mroszczak, D Freedman.   

Abstract

Studies have been carried out to investigate the disposition of nicardipine hydrochloride following intravenous and oral administration to male volunteers. Following oral administration of a radiolabelled dose, nicardipine was shown to be rapidly and extensively metabolised and to be rapidly eliminated from plasma. After intravenous infusion of nicardipine at 5 mg-1 for 3 h, plasma levels declined biexponentially, and clearance values were of the same order as hepatic blood flow. With repeated oral administration, 20 mg three times daily for 28 days, plasma levels rose over the first 3 days of administration and then declined to some extent. Possible reasons for this decline are discussed. Steady-state plasma levels and bioavailability show a nonlinear relationship with doses over the range 10-40 mg three times daily. Food consumption has been shown to reduce the bioavailability of nicardipine when the food is taken before or at the same time as nicardipine administration.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4027149      PMCID: PMC1400776          DOI: 10.1111/j.1365-2125.1985.tb05141.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

1.  Determination of a new cerebral vasodilator 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-[2-(N-benzyl-N-methylamino)]-ethyl ester 5-methyl ester hydrochloride (YC-93) in plasma by electron capture gas chromatography.

Authors:  S Higuchi; H Sasaki; T Sado
Journal:  J Chromatogr       Date:  1975-07-16

2.  Absorption, excretion and metabolism of a new dihydropyridine diester cerebral vasodilator in rats and dogs.

Authors:  S Higuchi; H Sasaki; Y Shiobara; T Sado
Journal:  Xenobiotica       Date:  1977-08       Impact factor: 1.908

3.  Pharmacokinetics of nicardipine following oral and intravenous administration in man.

Authors:  D J Graham; R J Dow; D Freedman; E Mroszczak; T Ling
Journal:  Postgrad Med J       Date:  1984       Impact factor: 2.401

4.  Comparative pharmacokinetics of nicardipine hydrochloride, a new vasodilator, in various species.

Authors:  S Higuchi; Y Shiobara
Journal:  Xenobiotica       Date:  1980-06       Impact factor: 1.908

5.  A high-performance liquid chromatographic method for the simultaneous determination of nicardipine and its pyridine metabolite II in plasma.

Authors:  A T Wu; I J Massey; S Kushinsky
Journal:  J Pharm Sci       Date:  1984-10       Impact factor: 3.534

6.  Pharmacokinetic studies on nicardipine hydrochloride, a new vasodilator, after repeated administration to rats, dogs and humans.

Authors:  S Higuchi; H Sasaki; T Seki
Journal:  Xenobiotica       Date:  1980-12       Impact factor: 1.908

  6 in total
  16 in total

1.  The cardiovascular effects of oral nifedipine and nicardipine: a double-blind comparison in healthy volunteers using transthoracic bioimpedance cardiography.

Authors:  S H Thomas; P Molyneux; J Kelly; S E Smith
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Simultaneous study of the pharmacokinetics of intravenous and oral nicardipine using a stable isotope.

Authors:  M Guerret; G Cheymol; M Hubert; C Julien-Larose; D Lavene
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 3.  Calcium channel antagonists: Part VI: Clinical pharmacokinetics of first and second-generation agents.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1989-08       Impact factor: 3.727

4.  Calcium channel antagonists and cyclosporine metabolism: in vitro studies with human liver microsomes.

Authors:  J F Tjia; D J Back; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1989-09       Impact factor: 4.335

Review 5.  Clinical pharmacokinetics of calcium antagonists. An update.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

6.  Comparison of nicardipine and propranolol in the treatment of mild and moderate hypertension.

Authors:  V A Naukkarinen; K Karppinen; S Sarna
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 7.  Pharmacokinetics of calcium antagonists under development.

Authors:  D R Abernethy; J B Schwartz
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

8.  Inhibitory effect of uraemia on the hepatic clearance and metabolism of nicardipine.

Authors:  J H Ahmed; A C Grant; R S Rodger; G R Murray; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

Review 9.  Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 1, drugs administered intravenously).

Authors:  Ryuichi Ogawa; Joan M Stachnik; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2013-03       Impact factor: 6.447

Review 10.  Calcium channel antagonists. Part V: Second-generation agents.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.